Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
A Dose-escalated Phase Ⅰ Trial to Assess the Tolerance and Pharmacokinetics of Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML Patient
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Terminated
Corporate policy adjustments
Other terminated trials from Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- ALK-positive Non-small Cell Lung Cancer · Phase PHASE2 · Oct 2022
- Myelodysplastic Syndromes · Phase PHASE1/PHASE2 · Jun 2022
- Nasopharyngeal Carcinoma · Phase PHASE1/PHASE2 · Oct 2021
- Differentiated Thyroid Cancer · Phase PHASE3 · Jul 2021
- Oesophageal Cancer · Phase PHASE1/PHASE2 · Oct 2020
More terminations from Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Other Acute Myeloid Leukemia (AML) trials with similar outcome
A PHASE1 clinical study on Acute Myeloid Leukemia (AML), this trial is terminated or withdrawn. The trial is conducted by Suzhou Zelgen Biopharmaceuticals Co.,Ltd and has accumulated 6 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2022 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Sep 2021 — Dec 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
▶ Show 1 earlier version
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Nov 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
For direct contact, visit the study record on ClinicalTrials.gov .